Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 47
LC-HRMS screens 9 GLP-1 agonists at once
A 2026 Hong Kong study validated a single LC-HRMS method covering nine GLP-1 receptor agonists, from approved drugs to investigational compounds.
Sports medicine peptides: the 2026 evidence
A 2026 UCLA scoping review found that the claimed benefits of BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu remain unsubstantiated by human trials.
Retatrutide and gallbladder disease risk
Retatrutide is an investigational GLP-1, GIP and glucagon triple agonist. Here is what the trial and label data show about gallbladder risk.
Obesity-driven HFpEF: the 2026 review
A 2026 systematic review maps how obesity drives HFpEF and frames SUMMIT trial data on tirzepatide into a practical clinical treatment approach.
COMBINE 4: IcoSema vs insulin glargine
COMBINE 4 put once-weekly IcoSema against daily insulin glargine U100 in type 2 diabetes. HbA1c fell further, and bodyweight moved the other way.
Compounded tirzepatide with B6 explained
Compounded tirzepatide, including preparations with added vitamin B6, is not the licensed medicine. Here is what is documented and what is not.
How GLP-1 weight loss drugs really differ
Novo's CEO says patients want optionality. Here is what the approved labels and the single head-to-head trial say really separates these drugs.
GLP-1 gastroparesis symptoms and the gaps
A 2026 systematic review found only 12 published case reports of GLP-1 gastroparesis. Here is what they showed, and what they cannot tell you.
GLP-1 drugs at longevity clinics
Longevity and aesthetic clinics prescribe semaglutide and tirzepatide off-label. Here is what the labels cover, and where the ageing evidence stops.
SS-31, MOTS-c, and Tesamorelin: Evidence
What the published research says about SS-31, MOTS-c, GHK-Cu, and tesamorelin when people consider adding them to a retatrutide regimen.
Peptide cycles per year: no number exists
Cycle lengths come from a few small trials. Cycle counts come from nowhere, because no study has tested repeating a peptide course across a year.
Tirzepatide, blood pressure, cholesterol
A SURMOUNT post hoc analysis scores tirzepatide on all three targets at once. Between 32% and 38% of participants hit every one. Composites read differently.